Background: Hypertension comes under the category of chronic disease, which requires long term treatment. Hypertension is usually treated by oral administration of various therapeutic agents. There are several limitations of the oral route, making pharmaceutical scientists to discover an alternative route for drug delivery.

Methods: The transdermal route may be a better alternative as it shows various advantages like lack of first-pass effect and high patient compliance. The skin may act as a primary barrier for the transdermal delivery of anti-hypertensive drugs; therefore, new approaches are required to cross this barrier. Nanocarrier systems come under these new approaches to cross the skin barrier. Various nanocarrier systems explored for transdermal delivery of antihypertensive drugs are liposomes, elastic liposomes, ethosomes, transethosomes, oleic acid vesicles, niosomes, solid lipid nanoparticles, nanostructured lipid carriers, nanoemulsions/microemulsions, and carbon nanotubes.

Results: This review summarizes the potential of advanced nanocarrier systems for effective management of hypertension following the transdermal route. The entire literature search regarding the utility of nanocarrier systems in transdermal delivery of antihypertensive drugs was done by using Pubmed and Google Scholar.

Conclusion: Nanocarrier systems are capable of reducing various drawbacks of conventional formulations of antihypertensive drugs like excessive first-pass effects, high dosing frequency, and toxicity promoting high patient compliance. However, the clinical efficacy determination of such nanocarrier systems is still a challenge and it will govern their presence in the global pharmaceutical market.

背景：高血压属于慢性病，需要长期治疗。高血压通常通过口服各种治疗剂来治疗。口服途径有几个局限性，使得药学科学家发现了另一种药物递送途径。

方法：透皮途径可能是更好的选择，因为它具有多种优点，例如缺乏首过效应和患者依从性高。皮肤可以作为抗高血压药物透皮给药的主要屏障；因此，需要新的方法来跨越这一障碍。纳米载体系统属于这些穿越皮肤屏障的新方法。用于抗高血压药物透皮递送的各种纳米载体系统是脂质体、弹性脂质体、乙醇脂质体、转乙醇脂质体、油酸囊泡、脂质体、固体脂质纳米颗粒、纳米结构脂质载体、纳米乳液/微乳液和碳纳米管。

结果：本综述总结了先进的纳米载体系统在经皮途径有效管理高血压方面的潜力。使用 Pubmed 和 Google Scholar 完成了有关纳米载体系统在抗高血压药物透皮递送中的效用的全部文献检索。

结论：纳米载体系统能够减少常规抗高血压药物制剂的各种缺点，如过度的首过效应、高给药频率和提高患者依从性的毒性。然而，这种纳米载体系统的临床疗效测定仍然是一个挑战，它将决定它们在全球医药市场的存在。